BAX326 (RIXUBIS): A novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B

Therapeutic Advances in Hematology

Volumn 5, Issue 5, 2014, Pages 168-180

  Windyga, Jerzy ^a   Solano Trujillo, Maria Helena ^b   Hafeman, Andrea E ^c  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^b Fundacion Universitaria de Ciencias de la Salud   (United States)

^c BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

health related quality of life; hemophilia B; pediatric; pharmacokinetics; prophylaxis; recombinant factor IX; safety; surgery

Indexed keywords

EID: 84993740343     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620714550573     Document Type: Review

References (50)

1. Aznar J. Magallón M. Querol F. Gorina E. Tusell J. (2000) The orthopaedic status of severe haemophiliacs in Spain. Haemoph Off J World Fed Hemoph 6: 170–176.
2. Baxter Healthcare Corporation (2014), RIXUBIS [Coagulation Factor IX (Recombinant)]. Available at: http://www.baxter.com/healthcare_professionals/products/rixubis.html (accessed 27 August 2014).
3. Berting A. Farcet M. Kreil T. (2010) Virus susceptibility of Chinese hamster ovary (CHO) cells and detection of viral contaminations by adventitious agent testing. Biotechnol Bioeng 106: 598–607.
4. Biss T. Chan A. Blanchette V. Iwenofu L. McLimont M. Carcao M. et al. (2008) The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemoph Off J World Fed Hemoph 14: 923–930.
5. Björkman S. Berntorp E. (2001) Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet 40: 815–832.
6. Brooker M. (2012) Registry of clotting factor concentrates, 9th edn. Report No. 6. Montreal, Canada: World Federation of Hemophilia.
7. CDC (2011) Universal data collection (UDC) system. Atlanta, GA: US Centers for Disease Control and Prevention.
8. Dietrich B. Schiviz A. Hoellriegl W. Horling F. Benamara K. Rottensteiner H. et al. (2013) Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B. Int J Hematol 98: 525–532.
9. Di Michele D. (2007) Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 138: 305–315.
10. Di Michele D. (2012) Immune tolerance in haemophilia: the long journey to the fork in the road. Br J Haematol 159: 123–134.
11. Elander J. Barry T. (2003) Analgesic use and pain coping among patients with haemophilia. Haemoph Off J World Fed Hemoph 9: 202–213.
12. Ewenstein B. Joist J. Shapiro A. Hofstra T. Leissinger C. Seremetis S. et al. (2002) Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion (Paris) 42: 190–197.
13. Franchini M. Frattini F. Crestani S. Sissa C. Bonfanti C. (2013) Treatment of hemophilia B: focus on recombinant factor IX. Biol Targets Ther 7: 33–38.
14. Furie B. Limentani S. Rosenfield C. (1994) A practical guide to the evaluation and treatment of hemophilia. Blood 84: 3–9.
15. Giordano P. Franchini M. Lassandro G. Faienza M. Valente R. Molinari A. (2013) Issues in pediatric haemophilia care. Ital J Pediatr 39: 24.
16. Gray E. Tubbs J. Thomas S. Oates A. Boisclair M. Kemball-Cook G. et al. (1995) Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity. Thromb Haemost 73: 675–679.
17. Gringeri A. Ewenstein B. Reininger A. (2014) The burden of bleeding in haemophilia: is one bleed too many? Haemoph Off J World Fed Hemoph 20: 459–463. Jan 29; Epub ahead of print
18. Key N. Negrier C. (2007) Coagulation factor concentrates: past, present, and future. Lancet 370: 439–448.
19. Kim I. Choi Y. Kang Y. Sung H. Sohn K. Kim Y. (2008) Improvement of virus safety of an antihemophilic factor IX by virus filtration process. J Microbiol Biotechnol 18: 1317–1325.
20. Kim H. McMillan C. White G. Bergman G. Horton M. Saidi P. (1992) Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood 79: 568–575.
21. Ludlam C. Turner M. (2006) Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products. Br J Haematol 132: 13–24.
22. Makris M. (2009) Is VIII worse than IX? Blood 114: 750–751.
23. Manco-Johnson M. Abshire T. Shapiro A. Riske B. Hacker M. Kilcoyne R. et al. (2007) Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 357: 535–544.
24. Mann K. (1999) Biochemistry and physiology of blood coagulation. Thromb Haemost 82: 165–174.
25. Mannucci P. Franchini M. (2013) Is haemophilia B less severe than haemophilia A? Haemoph Off J World Fed Hemoph 19: 499–502.
26. Maruish M. (2011) User's Manual for the SF-36v2 Health Survey, 3rd edn. Lincoln, RI: Quality Metric Incorporated.
27. Matino D. Lillicrap D. Astermark J. Dolan G. Kessler C. Lambert T. et al. (2014) Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity. Haemoph Off J World Fed Hemoph 20: 200–206.
28. Miners A. Sabin C. Tolley K. Jenkinson C. Kind P. Lee C. (1999) Assessing health-related quality-of-life in individuals with haemophilia. Haemoph Off J World Fed Hemoph 5: 378–385.
29. Molho P. Rolland N. Lebrun T. Dirat G. Courpied J. Croughs T. et al. (2000) Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. Haemoph Off J World Fed Hemoph 6: 23–32.
30. Negrier C. Knobe K. Tiede A. Giangrande P. Moss J. (2011) Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 118: 2695–2701.
31. Østergaard H. Bjelke J. Hansen L. Petersen L. Pedersen A. Elm T. et al. (2011) Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 118: 2333–2341.
32. Pfizer Inc. (2014), BeneFIX® coagulation factor IX (recombinant). Available at: http://www.pfizerpro.com/hemophilia/BENEFIX-Home (accessed 27 August 2014).
33. Poon M. Lillicrap D. Hensman C. Card R. Scully M. (2002) Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thromb Haemost 87: 431–435.
34. Rezvan H. Motallebi Z. Jalili M. Mousavi Hosseini K. Pourfathollah A. (2006) Safety of blood and plasma derivatives: pathogen reducing technologies. Med J Islam Repub Iran 20: 86–92.
35. Roth D. Kessler C. Pasi K. Rup B. Courter S. Tubridy K. et al. (2001) Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 98: 3600–3606.
36. Santagostino E. Negrier C. Klamroth R. Tiede A. Pabinger-Fasching I. Voigt C. et al. (2012) Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 120: 2405–2411.
37. Schulman S. Eelde A. Holmström M. Ståhlberg G. Odeberg J. Blombäck M. (2008) Validation of a composite score for clinical severity of hemophilia. J Thromb Haemost JTH 6: 1113–1121.
38. Shapiro A. Ragni M. Valentino L. Key N. Josephson N. Powell J. et al. (2012) Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 119: 666–672.
39. Solano Trujillo M. Stasyshyn O. Rusen L. Serban M. Lamas J. Perina F. et al. (2014) Safe switching from a pdFIX (Immunine®) to a rFIX (BAX326). Haemophilia, 20: 674–681.
40. Srivastava A. Brewer A. Mauser-Bunschoten E. Key N. Kitchen S. Llinas A. et al. (2013) Guidelines for the management of hemophilia. Haemoph Off J World Fed Hemoph 19: e1-e47.
41. Therapeutic Goods Administration (2014) Rixubis nonacog gamma, 500 IU, powder and solvent for solution for injection, glass vials. Report No. ARTG 204769. Canberra: Commonwealth of Australia.
42. Turecek P. Auer W. Rottensteiner H. Schrenk G. Hollriegl W. Schiviz A. Scheiflinger F. Schwarz H. Muchitsch E. (2013) Impact of factor IXa content on function, safety and efficacy of recombinant factor IX products. J Thromb Haemostasis. 11(Suppl. 2): 290–1019.
43. Urasinski T. Stasyshyn O. Andreeva T. Rusen L. Perina F. Oh M. et al. (2013) Pharmacokinetics, efficacy and safety of a recombinant factor IX (BAX326) in previously-treated pediatric patients <12 years of age with severe or moderately severe hemophilia B. Poster presented at the American Society of Hematology 55th Annual Meeting, New Orleans, LA.
44. Warrier I. Ewenstein B. Koerper M. Shapiro A. Key N. Di Michele D. et al. (1997) Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 19: 23–27.
45. WFH (2013) World Federation of Hemophilia report on the Annual Global Survey 2012. Montreal, Canada: World Federation of Hemophilia.
46. Windyga J. Lin V. Epstein J. Ito D. Xiong Y. Abbuehl B. et al. (2014 a) Improvement in health-related quality of life with recombinant factor IX prophylaxis in severe or moderately severe haemophilia B patients: results from the BAX 326 Pivotal Study. Haemophilia 20: 362–368.
47. Windyga J. Lissitchkov T. Stasyshyn O. Mamonov V. Ghandehari H. Chapman M. et al. (2014 b) Efficacy and safety of a recombinant factor IX (BAX326) in previously treated patients with severe or moderately severe hemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicenter, phase III study. Haemophilia 20: 651–658.
48. Windyga J. Lissitchkov T. Stasyshyn O. Mamonov V. Rusen L. Lamas J. et al. (2014 c) Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I / III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B. Haemophilia 20: 15–24.
49. White G. 2nd Beebe A. Nielsen B. (1997) Recombinant factor IX. Thromb Haemost 78: 261–265.
50. Yu Y. Millar C. (2014) Measurement of factor IX activity in plasma-derived and recombinant concentrates: insights from thrombin generation and activation-based assays. J Thromb Haemostasis, 12: 62–70.